Skip navigation
News & Events

News

Cord Blood America Announces Contract With BioE

"Provides Clients Highest Quality, 'State of the Art' Processing System for Cord Blood Storage"

January 27, 2010

 

 

LAS VEGAS, Jan. 21 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has contracted with BioE, St. Paul, Minnesota, to provide the newest "state of the art" cord blood processing systems for its Las Vegas operations.  This includes BioE's PrepaCyte® CB Processing System, which efficiently separates stem cells from cord blood for cryopreservation and eventual transplantation in humans.

The PrepaCyte CB Processing System:

  • Provides optimum stem cell recoveries on each cord blood unit processed.
  • Ensures the sterility and integrity of the cord blood unit.
  • Removes 99.5 percent of the unnecessary red cells, which offers a more pure concentration of stem cells compared to any other product or method in the industry.

"BioE's cord blood processing system helps Cord Blood America meet its objective of providing the highest quality of cord blood storage for our clients," said Matthew Schissler, co-founder and CEO.  "We are committed to offering our clients an unsurpassed level of processing and storage quality.  The BioE system does just that; one that our shareholders can revel in, and comforts our customers."  

About BioE, Inc.

Headquartered in St. Paul, Minn., BioE is a biomedical company that provides enabling cord blood stem cell tools and technologies.  The Company's proprietary PrepaCyte® CB Processing System easily and efficiently separates stem cells from cord blood for cryopreservation and eventual transplantation in humans.  BioE's clonal, cord blood-derived Multi-Lineage Progenitor Cell™ (MLPC™) stem cell – isolated using the company's PrepaCyte cell separation platform – can differentiate into multiple cell types and lineages and is readily available to clinicians and researchers for therapeutic research and drug discovery.  For more information about the company, visit www.bioe.com or contact Gayl Chrysler at (800)350-6466 (